DNA Sliding Clamps as Therapeutic Targets

Chromosomal DNA replication is achieved by an assembly of multi-protein complexes at the replication fork. DNA sliding clamps play an important role in this assembly and are essential for cell viability. Inhibitors of bacterial (β-clamp) and eukaryal DNA clamps, proliferating cell nuclear antigen (P...

Full description

Bibliographic Details
Main Authors: Amanda S. Altieri, Zvi Kelman
Format: Article
Language:English
Published: Frontiers Media S.A. 2018-10-01
Series:Frontiers in Molecular Biosciences
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fmolb.2018.00087/full
id doaj-22968dbc2fab4a48a9c8b6d4c01bd3e8
record_format Article
spelling doaj-22968dbc2fab4a48a9c8b6d4c01bd3e82020-11-25T00:40:33ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2018-10-01510.3389/fmolb.2018.00087383372DNA Sliding Clamps as Therapeutic TargetsAmanda S. Altieri0Zvi Kelman1Zvi Kelman2Institute for Bioscience and Biotechnology Research, University of Maryland and the National Institute of Standards and Technology, Rockville, MD, United StatesInstitute for Bioscience and Biotechnology Research, University of Maryland and the National Institute of Standards and Technology, Rockville, MD, United StatesBiomolecular Labeling Laboratory, Institute for Bioscience and Biotechnology Research, National Institute of Standards and Technology, Rockville, MD, United StatesChromosomal DNA replication is achieved by an assembly of multi-protein complexes at the replication fork. DNA sliding clamps play an important role in this assembly and are essential for cell viability. Inhibitors of bacterial (β-clamp) and eukaryal DNA clamps, proliferating cell nuclear antigen (PCNA), have been explored for use as antibacterial and anti-cancer drugs, respectively. Inhibitors for bacterial β-clamps include modified peptides, small molecule inhibitors, natural products, and modified non-steroidal anti-inflammatory drugs. Targeting eukaryotic PCNA sliding clamp in its role in replication can be complicated by undesired effects on healthy cells. Some success has been seen in the design of peptide inhibitors, however, other research has focused on targeting PCNA molecules that are modified in diseased states. These inhibitors that are targeted to PCNA involved in DNA repair can sensitize cancer cells to existing anti-cancer therapeutics, and a DNA aptamer has also been shown to inhibit PCNA. In this review, studies in the use of both bacterial and eukaryotic sliding clamps as therapeutic targets are summarized.https://www.frontiersin.org/article/10.3389/fmolb.2018.00087/fullβ-clampDNA clampDNA sliding clampproliferating cell nuclear antigenPCNAtherapeutic
collection DOAJ
language English
format Article
sources DOAJ
author Amanda S. Altieri
Zvi Kelman
Zvi Kelman
spellingShingle Amanda S. Altieri
Zvi Kelman
Zvi Kelman
DNA Sliding Clamps as Therapeutic Targets
Frontiers in Molecular Biosciences
β-clamp
DNA clamp
DNA sliding clamp
proliferating cell nuclear antigen
PCNA
therapeutic
author_facet Amanda S. Altieri
Zvi Kelman
Zvi Kelman
author_sort Amanda S. Altieri
title DNA Sliding Clamps as Therapeutic Targets
title_short DNA Sliding Clamps as Therapeutic Targets
title_full DNA Sliding Clamps as Therapeutic Targets
title_fullStr DNA Sliding Clamps as Therapeutic Targets
title_full_unstemmed DNA Sliding Clamps as Therapeutic Targets
title_sort dna sliding clamps as therapeutic targets
publisher Frontiers Media S.A.
series Frontiers in Molecular Biosciences
issn 2296-889X
publishDate 2018-10-01
description Chromosomal DNA replication is achieved by an assembly of multi-protein complexes at the replication fork. DNA sliding clamps play an important role in this assembly and are essential for cell viability. Inhibitors of bacterial (β-clamp) and eukaryal DNA clamps, proliferating cell nuclear antigen (PCNA), have been explored for use as antibacterial and anti-cancer drugs, respectively. Inhibitors for bacterial β-clamps include modified peptides, small molecule inhibitors, natural products, and modified non-steroidal anti-inflammatory drugs. Targeting eukaryotic PCNA sliding clamp in its role in replication can be complicated by undesired effects on healthy cells. Some success has been seen in the design of peptide inhibitors, however, other research has focused on targeting PCNA molecules that are modified in diseased states. These inhibitors that are targeted to PCNA involved in DNA repair can sensitize cancer cells to existing anti-cancer therapeutics, and a DNA aptamer has also been shown to inhibit PCNA. In this review, studies in the use of both bacterial and eukaryotic sliding clamps as therapeutic targets are summarized.
topic β-clamp
DNA clamp
DNA sliding clamp
proliferating cell nuclear antigen
PCNA
therapeutic
url https://www.frontiersin.org/article/10.3389/fmolb.2018.00087/full
work_keys_str_mv AT amandasaltieri dnaslidingclampsastherapeutictargets
AT zvikelman dnaslidingclampsastherapeutictargets
AT zvikelman dnaslidingclampsastherapeutictargets
_version_ 1725289403478179840